Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, Denmeade S, Carducci M, Eisenberger M, DeWeese TL, Orton M, Deville C, Davicioni E, Liauw SL, Heath EI, Greco S, Desai NB, Spratt DE, Feng F, Wang H, Beer TM, Antonarakis ES. Tran PT, et al. Among authors: feng f. J Clin Oncol. 2023 Feb 20;41(6):1307-1317. doi: 10.1200/JCO.22.01662. Epub 2022 Nov 11. J Clin Oncol. 2023. PMID: 36367998 Free PMC article. Clinical Trial.
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY. Jackson WC, et al. Radiat Oncol. 2013 Jul 8;8:170. doi: 10.1186/1748-717X-8-170. Radiat Oncol. 2013. PMID: 23835115 Free PMC article.
Time to Nadir PSA: Of Popes and PSA--The Immortality Bias.
Johnson SB, Jackson WC, Murgic J, Feng FY, Hamstra DA. Johnson SB, et al. Am J Clin Oncol. 2015 Oct;38(5):465-71. doi: 10.1097/COC.0b013e3182a468b2. Am J Clin Oncol. 2015. PMID: 24064749 Clinical Trial.
Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.
Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Den RB, et al. Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1038-1046. doi: 10.1016/j.ijrobp.2014.04.052. Epub 2014 Jul 8. Int J Radiat Oncol Biol Phys. 2014. PMID: 25035207 Free PMC article.
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY. Prensner JR, et al. Lancet Oncol. 2014 Dec;15(13):1469-1480. doi: 10.1016/S1470-2045(14)71113-1. Epub 2014 Nov 17. Lancet Oncol. 2014. PMID: 25456366 Free PMC article.
Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. Tomlins SA, et al. Eur Urol. 2015 Oct;68(4):555-67. doi: 10.1016/j.eururo.2015.04.033. Epub 2015 May 8. Eur Urol. 2015. PMID: 25964175 Free PMC article.
3,568 results